Bibliography

Lung Cancer Models

• Gazdar AF, Carney DN, Russell EK, Sims HL, Baylin SB, Bunn PA, Jr., et al. Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res 1980;40:3502-7.
• Gazdar AF, Carney DN, Sims HL, Simmons A. Heterotransplantation of small-cell carcinoma of the lung into nude mice: comparison of intracranial and subcutaneous routes. Int J Cancer 1981;28:777-83.
• Brower M, Carney DN, Oie HK, Gazdar AF, Minna JD. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res 1986;46:798-806.
• Gazdar AF, Minna JD. NCI series of cell lines: an historical perspective. J Cell Biochem Suppl 1996;24:1-11.
• Wistuba II, Bryant D, Behrens C, Milchgrub S, Virmani AK, Ashfaq R, et al. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res 1999;5:991-1000
• Gazdar AF, Gao B, Minna JD. Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer 2010.

Breast Cancer Models

• Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 1998;78:766-74.
• Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009;4:e6146.

Pediatric Cancer Models

• Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, Smith RG: Characterization of human neuroblastoma cell lines established before and after therapy. J National Cancer Institute 1986; 76:375-387.
• Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998;58:5396-405.
• Keshelava N, Zuo JJ, Chen P, Waidyaratne NS, Luna MC, Gomer CJ, et al. Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. Cancer Res 2001;61:5103-5.
• Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 2007;67:32-40.
• Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008;14:4572-83.

Cell Line Molecular Identification

• Cabral D, Feaman H, Sheard M, Reynolds C. Short tandem repeat genotyping using Identifiler TM is a reproducible and cost-effective method for establishing and monitoring identity of pediatric cancer cell lines. Proc Amer Assoc Cancer Res 2007;48:96.

In Vitro Drug Testing Methodology

• Grigoryan R, Keshelava N, Anderson C, Reynolds CP. In vitro testing of chemosensitivity in physiological hypoxia. Methods Mol Med 2005;110:87-100.
• Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds CP. DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 2005;110:139-53.
• Frgala T, Kalous O, Proffitt RT, Reynolds CP. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007;6:886-97.
• Kang MH, Smith MA, Morton C, Keshelava N, Houghton P, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model description for in vitro cytotoxicity testing. Pediatric Blood & Cancer, Epub Oct 4, 2010.
• Reynolds CP, Maurer BJ. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med 2005;110:173-83.

In Vivo Drug Testing Methodology

• Reynolds CP, Sun BC, DeClerck YA, Moats RA. Assessing growth and response to therapy in murine tumor models. Methods Mol Med 2005;111:335-50.
• Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007;110:2057-66.
• Maurer BJ, Kalous O, Yesair DW, Wu X, Janeba J, Maldonado V, et al. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res 2007;13:3079-86.
• Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008;14:4572-83.
• Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:799-805.